PCM
SLDB icon

Polymer Capital Management’s Solid Biosciences SLDB Stock Holding History

Polymer Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,264
Closed -$94.2K – 972
2025
Q3 		$94.2K Buy
+15,264
New +$89.3K 0.01% 735

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Polymer Capital Management's SLDB Position: Q4 2025 in Review

Polymer Capital Management sold out of Solid Biosciences (SLDB) in Q4 2025, closing a stake of 15,264 shares — an estimated $94.2K sold.

Polymer Capital Management first reported a position in SLDB in Q3 2025 and held it in 1 quarter. The position peaked at $94.2K in Q3 2025. 130 funds tracked by Wall St. Rank hold SLDB as of Q4 2025.

  • Polymer Capital Management reported no remaining Solid Biosciences position as of Q4 2025 after selling out during the quarter.
  • Polymer Capital Management sold 15,264 Solid Biosciences shares in Q4 2025, an estimated $94.2K.
  • Polymer Capital Management first reported a position in Solid Biosciences in Q3 2025 and held it in 1 quarter.
  • Polymer Capital Management's Solid Biosciences position peaked at $94.2K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2025.

Based on Polymer Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.